Cue Biopharma Q1 2024 Earnings Report

Cue Biopharma EPS Results

• Actual EPS: -$225.00
• Consensus EPS: -$270.00
• Beat/Miss: Beat by +$45.00
• One Year Ago EPS: N/A

Cue Biopharma Revenue Results

• Actual Revenue: $1.72 million
• Expected Revenue: $0.73 million
• Beat/Miss: Beat by +$990.00 thousand
• YoY Revenue Growth: N/A

Cue Biopharma Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: N/A
• Conference Call Date: Thursday, May 9, 2024
• Conference Call Time: 4:00PM ET

Cue Biopharma (NASDAQ:CUE) is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies. Its most advanced candidate, CUE-101, is an HLA‐peptide‐cytokine fusion designed to stimulate T cells specific to HPV16‐positive cancers. Additional programs—such as CUE-102 and CUE-301—seek to address solid tumors and viral infections by harnessing the same platform technology to selectively expand disease-relevant T cell populations. The company’s research and manufacturing activities are conducted primarily in the United States, with collaborations and partnerships aimed at accelerating clinical development.

Under the leadership of President and CEO Darren Cline, Cue Biopharma has completed its initial public offering in 2021 and continues to build its research capabilities through strategic alliances with academic institutions and contract development organizations. The management team combines expertise in immunology, protein engineering and clinical development, positioning the company to advance its pipeline toward key clinical milestones. With its unique CRT platform, Cue Biopharma seeks to offer differentiated, antigen‐specific immunotherapies that may overcome limitations of current cytokine and cell‐based treatments.